CClinicalTrials.gg
Sign In
CompletedNCT0264075514CUpdated Apr 22, 2019Results posted

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase

A Phase 1 interventional study of [14C]AZD2014 and Multiple dose AZD2014 in Solid Malignancies, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-04-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts:

  1. Single Dose Period - will characterise the absorption, metabolism, excretion and pharmacokinetics of a single oral dose of [14C]AZD2014 from the body
  2. Multiple Dose Period - will further assess the safety and tolerability and anti-tumour activity of multiple doses of AZD2014 when given as a monotherapy or given in combination with paclitaxel or fulvestrant.
Read the detailed description

This is a Phase I, open label, single centre, non-randomised study in patients with advanced solid malignancies that is refractory or resistant to standard treatment or where no suitable effective standard treatment exists or for whom paclitaxel or fulvestrant are appropriate treatment choices. The study will be divided in two parts:

  1. Single Dose Period - will enrol up to 6 evaluable patients to characterise the absorption, metabolism, excretion and pharmacokinetics of a single radiolabelled [14C] oral dose of 125mg AZD2014 via residential intensive PK sampling over 8 days. An evaluable patient is defined as patient who does not vomit within 2 hours post dose and who has completed the scheduled PK sampling.
  2. Multiple Dose Period - patients who have completed the Single Dose Period may continue to receive treatment as outpatients. Patients will be allocated to different treatment regimes as decided between Investigator and patient on a risk / benefit basis. From Day 1, Cycle 1, non-radiolabelled AZD2014 treatment will be administered as oral tablets to patients, either as:

i. 50mg BD monotherapy ii. 125mg BD taken on first 2 days of treatment each week in combination with 500mg intramuscular fulvestrant on Day 1, Cycle 1, Day 15, Cycle 1; Day 1, Cycle 2, then Day 1 of each monthly cycle thereafter iii. 50mg BD taken on first 3 days of treatment each week for 6 weeks in combination with a single weekly paclitaxel infusion (80mg/m2 ) followed by a one week break from treatment where no AZD2014 or paclitaxel will be given. This 7 week schedule composes one cycle of treatment. Patients will be given up to 6 cycles of paclitaxel, although additional cycles of paclitaxel may be given if deemed appropriate by the Investigator.

Radiolabelled AZD2014 will be administered to fasted patients (i.e. no food 2 hours before and 1 hour after each dose). Non-radiolabelled AZD2014 will be administered either under fasted or non-fasted conditions. The safety and tolerability and anti-tumour activity of AZD2014 and combination with paclitaxel or fulvestrant will be evaluated in all enrolled patients respectively using conventional safety parameters, AEs/SAEs and RECIST 1.1.

02

Conditions studied

  • Solid Malignancies

Browse trials for

Keywords

  • Radiolabelled
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 4 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Provision of signed, written \& dated informed consent prior to any study specific procedures.
  • Male or female patients aged at least 18 years.
  • Have a body mass index (BMI) ≥18 kg/m2 and ≤35 kg/m2 \& weigh at least 50 kg.
  • Histological or cytological confirmation of a solid malignant tumour that is refractory or resistant to standard therapies or for which no suitable effective standard therapies exist. SqNSCLC patients are excluded from the 50mg BD AZD2014 in combination with paclitaxel cohort.
  • For patients intending to enter combination therapy with fulvestrant or paclitaxel, this should be deemed as an appropriate treatment option by Investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with no deterioration over previous 2 weeks \& minimum life expectancy of 12 weeks.
  • At least one lesion (measurable and/or non-measurable but evaluable) that can be accurately assessed at baseline by computerised tomography (CT) magnetic resonance imaging (MRI) or plain X-ray \& is suitable for repeated assessment
  • Able \& willing to stay in hospital for approximately 9 days
  • Females should be using adequate contraceptive measures, should not be breast feeding \& must have negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential
  • Male patients should be surgically sterile or willing to use barrier contraception ie, condoms and spermicide \&refrain from donating sperm from start of dosing until 16 weeks after discontinuing of study treatment.
  • Regular bowel movements (ie, on average production of at least 1 stool per day)

Exclusion criteria

Exclusion Criteria:

  • Involvement in planning and/or conduct of the study
  • Previous enrolment in present study
  • Another study with an investigational product in last 28 days
  • Chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents \& any investigational agents within 21 days of starting treatment (not including palliative radiotherapy at focal sites), or corticosteroids within 14 days
  • Major surgery within 4 weeks, or minor surgery within 14 days
  • Exposure to strong and moderate inhibitors or inducers of cytochrome P450 (CYP) 3A4/5, P-glycoprotein (Pgp) (multidrug resistance gene [MDR1]), and breast cancer resistance protein (BCRP), if taken within stated washout periods
  • Exposure to specific substrates of the drug organic anion-transporting polypeptide (OATP)1B1, OATP1B3, organic anion transporting polypeptide (OCT)1 and OCT2 within appropriate washout period
  • Any haemopoietic growth factors (eg, filgrastim [granulocyte colony-stimulating factor; G-CSF], sargramostim [granulocyte-macrophage colony-stimulating factor; GM-CSF]) within 14 days prior to receiving study treatment
  • Previous treatment with AZD2014 or AZD8055
  • Patients who have received fulvestrant within 3 months
  • With exception of alopecia, any unresolved toxicities chemotherapy/radiotherapy should be no greater than CTCAE grade 1
  • Participated in another absorption, distribution, metabolism and excretion study within 1 year
  • Spinal cord compression and/or brain metastases unless asymptomatic or treated \& stable off steroids for at least 4 weeks
  • Severe or uncontrolled systemic diseases (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]), or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, active bleeding diatheses or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
  • Recent history of drug abuse or alcohol abuse

  • Patients who have undergone any of the following procedures or experienced conditions currently or in preceding 12 months:

    • Coronary artery bypass graft
    • Angioplasty
    • Vascular stent
    • Myocardial infarction
    • Angina pectoris
    • Congestive heart failure New York Heart Association Grade 2
    • Ventricular arrhythmias requiring continuous therapy
    • Uncontrolled supraventricular arrhythmias including atrial fibrillation
    • Haemorrhagic or thrombotic stroke, including transient ischaemic attacks or other central nervous system bleeding
  • Abnormal echocardiogram at baseline (left ventricular ejection fraction [LVEF] \<55% and shortening fraction [SF] \<15%)
  • Torsades de Pointes either currently or within 12 months
  • Mean resting QTcF ≥470 ms
  • Medications known to prolong QT interval, or that increase the risk of QTc prolongation or arrhythmic events (such as heart failure, hypokalaemia, congenital long QT syndrome, family history of either long QT syndrome), or unexplained sudden death under 40 years of age

  • Laboratory values as listed below:

    • Absolute neutrophil count \<1.5x109/L
    • Platelet count \<100x109/L
    • Haemoglobin \<90 g/L
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or >5xULN in the presence of liver metastases
    • Total bilirubin >1.5xULN if no demonstrable liver metastases or >3xULN in the presence of liver metastases
    • Serum creatinine >1.5xULN concurrent with creatinine clearance \<50 mL/min (measured or calculated by Cockcroft and Gault equation), confirmation of creatinine clearance is only required when creatinine is >1.5xULN
    • Clinically relevant and treatment resistant abnormalities in potassium, sodium, calcium (corrected for plasma albumin) or magnesium
  • Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis
  • Abnormal fasting glucose >126 mg/dL (>7 mmol/L)
  • Patients with diabetes Type 1 or uncontrolled Type 2 (glycosylated haemoglobin [HbA1c] >8% [64 mmol/mol] assessed locally)
  • Current refractory nausea and vomiting, chronic gastrointestinal disease or inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption
  • History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014
  • Judgment that patient is unsuitable to participate in study and unlikely to comply with study procedures, restrictions \& requirements
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    [14C]AZD2014 followed by AZD2014 Monotherapy

    Arm will be comprised of \[14C\]AZD2014 followed by AZD2014 Monotherapy

    Drug: [14C]AZD2014 · Drug: Multiple dose AZD2014

  • Experimental
    [14C]AZD2014 followed by AZD2014 + Fulvestrant

    Arm will be comprised of \[14C\]AZD2014 followed by AZD2014 + Fulvestrant

    Drug: [14C]AZD2014 · Drug: Multiple dose AZD2014 · Drug: Fulvestrant

  • Experimental
    [14C]AZD2014 followed by AZD2014 + Paclitaxel

    Arm will be comprised of \[14C\]AZD2014 followed by AZD2014 + Paclitaxel

    Drug: [14C]AZD2014 · Drug: Multiple dose AZD2014 · Drug: Paclitaxel

Interventions

  • Drug[14C]AZD2014

    Radiolabelled dual TORC1/TORC2 inhibitor

  • DrugMultiple dose AZD2014

    Dual TORC1/TORC2 inhibitor

  • DrugFulvestrant

    Hormonal Agent

  • DrugPaclitaxel

    Taxane

06

What researchers measure

Primary outcomes

  1. Total Radioactivity in Plasma Following Administration of [14C]-AZD2014

    The mean concentrations of total radioactivity in plasma collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of plasma sampling up to 48 hours post-dose. Geometric mean concentrations were not quantifiable after 48 hours. The total \[14C\] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32 and 48 hours (h) post [14C]-AZD2014 dose in the Single Dose Period.

  2. AZD2014 Concentrations in Plasma Following Administration of [14C]-AZD2014

    The mean concentrations of AZD2014 in plasma collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of plasma sampling up to 24 hours post-dose. Geometric mean concentrations were not quantifiable after 24 hours.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.

  3. Total Radioactivity Concentrations in Saliva Following Administration of [14C]-AZD2014

    The mean concentrations of total radioactivity in saliva collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of saliva collection up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours. The total \[14C\] radioactivity in saliva was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

    Time frame: Saliva was collected at 1, 2, 4, 6, 8, 10 and 12 h post [14C]-AZD2014 dose in the Single Dose Period.

  4. AZD2014 Concentrations in Saliva Following Administration of [14C]-AZD2014

    The mean concentrations of AZD2014 in saliva collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of plasma sampling up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours.

    Time frame: Saliva was collected at 1, 2, 4, 6, 8, 10 and 12 h post [14C]-AZD2014 dose in the Single Dose Period.

  5. Total Radioactivity Concentrations in Blood Following Administration of [14C]-AZD2014

    The mean concentrations of total radioactivity in blood collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of blood sampling up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours. The total \[14C\] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post [14C]-AZD2014 dose in the Single Dose Period.

  6. Cumulative Percentage of [14C]-AZD2014 Recovered by Day 8

    The mean cumulative percentage of \[14C\]-AZD2014 dose recovered as total radioactivity by the end of the Single Dose Period (Day 1 - 8) is presented. The total \[14C\] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

    Time frame: From pre-dose Day 1 to Day 8 of the Single Dose Period.

  7. Maximum Observed Concentration (Cmax) of AZD2014 in Plasma and Saliva

    Mean AZD2014 Cmax values in plasma and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.

  8. Time to Maximum Observed Concentration (Tmax) for AZD2014 in Plasma and Saliva

    AZD2014 Tmax values for plasma and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.

  9. Time to Last Measurable Concentration (t[Last]) for AZD2014 in Plasma and Saliva

    AZD2014 t(last) values in plasma and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.

  10. Area Under the Plasma Concentration-time Curve (AUC) for AZD2014

    Mean AUC for AZD2014 following administration of \[14C\]-AZD2014 on Day 1 is presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.

  11. Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) for AZD2014 in Plasma and Saliva

    Mean AUC(0-t) values in plasma and saliva for AZD2014 following administration of \[14C\]-AZD2014 on Day 1 are presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.

  12. Apparent Total Body Clearance (CL/F) of AZD2014

    The mean CL/F of AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.

  13. Mean Residence Time (MRT) of AZD2014

    The MRT of AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.

  14. Apparent Volume of Distribution at Steady State (Vss/F) for AZD2014 in Plasma

    The mean Vss/F of AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.

  15. Terminal Elimination Rate Constant (lambda_z) for AZD2014 in Plasma

    The mean lambda_z of AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.

  16. Half-life Associated With Terminal Slope (lambda_z) of a Semi-logarithmic Concentration-time Curve (t1/2[lambda_z]) for AZD2014 in Plasma

    The mean t1/2(lambda_z) for AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h ost [14C]-AZD2014 dose in the Single Dose Period.

  17. Cmax for Total [14C] Radioactivity in Whole Blood and Saliva

    Mean \[14C\] radioactivity Cmax values in whole blood and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.

  18. Tmax for [14C] Radioactivity in Whole Blood and Saliva

    \[14C\] radioactivity tmax in whole blood and saliva following administration of \[14C\]-AZD2014 on Day 1 is presented .

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.

  19. T(Last) for [14C] Radioactivity in Whole Blood and Saliva

    Mean \[14C\] radioactivity t(last) values in whole blood and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.

  20. Ratio of Whole Blood Total Radioactivity to Plasma Total Radioactivity

    The mean ratios of whole blood total radioactivity to plasma total radioactivity are presented for the timepoints of sample collection up to 12 hours post-dose. Geometric mean ratios were not calculated after 12 hours.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post [14C]-AZD2014 dose.

  21. Ratio of AZD2014 Concentration to Total Radioactivity Concentration in Saliva

    The mean ratios of saliva AZD2014 to saliva radioactivity concentrations are presented for the timepoints of saliva collection up to 10 hours post-dose. Geometric mean ratios were not calculated after 10 hours. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

    Time frame: Saliva was collected at 1, 2, 4, 6, 8 and 10 h post [14C]-AZD2014 dose in the Single Dose Period.

  22. Fraction of AZD2014 Excreted in Urine as a Percentage of the Dose (fe%[R])

    Mean fe%(R) values per urine collection period are presented as a percentage of the total \[14C\]-AZD2014 dose administered on Day 1.

    Time frame: Urine was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period.

  23. Renal Clearance (CL[R]) of AZD2014 From Plasma.

    CL(R) of AZD2014 from plasma up to 168 h post-dose.

    Time frame: Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.

  24. Cumulative Percentage of Total [14C] Radioactivity Excreted in Urine as a Percentage of the Dose (fe Cum%[R])

    fe cum%(R) by the end of each collection period is presented following administration of \[14C\]-AZD2014. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

    Time frame: Urine was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period.

  25. Cumulative Percentage of Total [14C] Radioactivity Excreted in Stool as a Percentage of the Dose (fe Cum%[f])

    fe cum%(f) by the end of each collection period is presented following administration of \[14C\]-AZD2014. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

    Time frame: Stool was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period.

Secondary outcomes

  1. Number of AEs Experienced by Patients.

    AEs (including serious AEs \[SAEs\]) were collected from the time of informed consent (Visit 1) and throughout the study, including the 30-day follow-up. The numbers of patients experiencing any AEs and SAEs, causally related AEs and SAEs, and SAEs which were fatal are presented.

    Time frame: From Day 1 of the Single Dose Period to 30 days after the last dose of AZD2014 administered in the Multiple Dose Period.

  2. Best Overall Response (BOR) Assessment

    Anti-tumour activity through assessment of BOR. BOR was defined for each patient as follows according to the RECIST 1.1 criteria: Complete Response (CR): Disappearance of all target lesions since baseline. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions. Stable Disease (SD): Any cases that do not qualify for either PR or progressive disease (PD). PD: At least a 20% increase in the sum of the diameters of target lesions. BOR for each patient was determined as the best response recorded from the day study treatment started until progression or until the last evaluable RECIST tumour assessment in the absence of progression.

    Time frame: RECIST 1.1 assessments were performed pre-dose at screening and then once every 8 weeks relative to the start of treatment in the Multiple Dose Period.

  3. Best Percentage Change in Tumour Size From Baseline

    Assessment of anti-tumour activity through measurement of tumour lesions. Tumour size was defined as the sum of the lengths of the longest diameters of the RECIST 1.1 target lesions.

    Time frame: RECIST 1.1 assessments were performed pre-dose at screening and then once every 8 weeks relative to the start of treatment in the Multiple Dose Period.

07

Results

Posted Apr 22, 2019
Limitations and caveats
No patients were recruited into AZD2014 + paclitaxel treatment regimen, as per the protocol plan.

Participant flow

First subject enrolled: 8 February 2016; Last Subject Last Visit: 21 December 2016 (End of Study \[EoS\]). The study was performed at a single study centre in the United Kingdom. Adult patients with advanced solid tumours refractory or resistant to standard therapies were recruited into this 2 period study.

Single Dose Period (Day 1 - 8)
Participant flow — Single Dose Period (Day 1 - 8)
Milestone[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + Fulvestrant
Started31
Completed31
Not completed00
Multiple Dose Period (Day 8 - EoS)
Participant flow — Multiple Dose Period (Day 8 - EoS)
Milestone[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + Fulvestrant
Started31
Completed10
Not completed21
Withdrew: Condition under investigation worsened01
Withdrew: Subjective progression of disease10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryTotal Radioactivity in Plasma Following Administration of [14C]-AZD2014

The mean concentrations of total radioactivity in plasma collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of plasma sampling up to 48 hours post-dose. Geometric mean concentrations were not quantifiable after 48 hours. The total \[14C\] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32 and 48 hours (h) post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · nanogram equivalent/millilitre (ngEq/mL)
Total Radioactivity in Plasma Following Administration of [14C]-AZD2014
nanogram equivalent/millilitre (ngEq/mL)[14C]-AZD2014 (Period 1 [Day 1 - 8])
0.5 h (n = 3)4013 ± 41.55
1 h (n = 4)3415 ± 40.69
1.5 h (n = 4)2901 ± 34.87
2 h (n = 4)2693 ± 36.75
3 h (n = 4)2105 ± 38.82
4 h (n = 4)1818 ± 37.85
6 h (n = 4)1419 ± 37.31
8 h (n = 4)914.1 ± 42.85
12 h (n = 4)478.6 ± 47.42
24 h (n = 4)97.16 ± 35.55
32 h (n = 4)45.68 ± 35.92
48 h (n = 3)27.21 ± 43.22
PrimaryAZD2014 Concentrations in Plasma Following Administration of [14C]-AZD2014

The mean concentrations of AZD2014 in plasma collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of plasma sampling up to 24 hours post-dose. Geometric mean concentrations were not quantifiable after 24 hours.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · ng/mL
AZD2014 Concentrations in Plasma Following Administration of [14C]-AZD2014
ng/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
0.5 h (n = 3)3704 ± 29.79
1 h (n = 4)3090 ± 39.49
1.5 h (n = 4)2758 ± 26.33
2 h (n = 4)2409 ± 22.11
3 h (n = 4)1768 ± 26.45
4 h (n = 4)1439 ± 43.74
6 h (n = 4)917.7 ± 8.278
8 h (n = 4)619.4 ± 40.08
12 h (n = 4)314.6 ± 67.36
24 h (n = 2)35.11 ± 103.2
PrimaryTotal Radioactivity Concentrations in Saliva Following Administration of [14C]-AZD2014

The mean concentrations of total radioactivity in saliva collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of saliva collection up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours. The total \[14C\] radioactivity in saliva was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

Time frame:
Saliva was collected at 1, 2, 4, 6, 8, 10 and 12 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · ngEq/mL
Total Radioactivity Concentrations in Saliva Following Administration of [14C]-AZD2014
ngEq/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
1 h (n = 2)5495 ± 89.69
2 h (n = 3)650.2 ± 52.98
4 h (n = 3)264.3 ± 62.10
6 h (n = 3)135.4 ± 73.87
8 h (n = 3)158.5 ± 33.15
10 h (n = 3)105.2 ± 39.57
12 h (n = 3)104.0 ± 48.01
PrimaryAZD2014 Concentrations in Saliva Following Administration of [14C]-AZD2014

The mean concentrations of AZD2014 in saliva collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of plasma sampling up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours.

Time frame:
Saliva was collected at 1, 2, 4, 6, 8, 10 and 12 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · ng/mL
AZD2014 Concentrations in Saliva Following Administration of [14C]-AZD2014
ng/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
1 h (n = 3)4159 ± 84.68
2 h (n = 4)416.3 ± 84.85
4 h (n = 4)169.1 ± 52.50
6 h (n = 4)75.08 ± 40.23
8 h (n = 4)73.27 ± 15.19
10 h (n = 3)32.59 ± 60.47
12 h (n = 2)33.96 ± 69.25
PrimaryTotal Radioactivity Concentrations in Blood Following Administration of [14C]-AZD2014

The mean concentrations of total radioactivity in blood collected from each patient who received a single oral dose of 125 mg \[14C\]-AZD2014 are presented for time points of blood sampling up to 12 hours post-dose. Geometric mean concentrations were not quantifiable after 12 hours. The total \[14C\] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · ngEq/mL
Total Radioactivity Concentrations in Blood Following Administration of [14C]-AZD2014
ngEq/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
0.5 h (n = 3)2725 ± 38.13
1 h (n = 4)2293 ± 42.50
1.5 h (n = 4)1980 ± 36.01
2 h (n = 4)1783 ± 36.48
3 h (n = 4)1421 ± 38.64
4 h (n = 4)1255 ± 37.07
6 h (n = 4)964.9 ± 39.01
8 h (n = 4)632.1 ± 43.65
12 h (n = 4)345.0 ± 44.17
PrimaryCumulative Percentage of [14C]-AZD2014 Recovered by Day 8

The mean cumulative percentage of \[14C\]-AZD2014 dose recovered as total radioactivity by the end of the Single Dose Period (Day 1 - 8) is presented. The total \[14C\] radioactivity in plasma was converted to concentration equivalents of AZD2014 based on the actual specific activity of the dose. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

Time frame:
From pre-dose Day 1 to Day 8 of the Single Dose Period.
Reported as:
Mean · Percentage of dose administered
Cumulative Percentage of [14C]-AZD2014 Recovered by Day 8
Percentage of dose administered[14C]-AZD2014 (Period 1 [Day 1 - 8])
Cumulative Percentage of [14C]-AZD2014 Recovered by Day 892.02 ± 1.994
PrimaryMaximum Observed Concentration (Cmax) of AZD2014 in Plasma and Saliva

Mean AZD2014 Cmax values in plasma and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of AZD2014 in Plasma and Saliva
ng/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
Cmax in plasma4254 ± 37.73
Cmax in saliva5410 ± 94.34
PrimaryTime to Maximum Observed Concentration (Tmax) for AZD2014 in Plasma and Saliva

AZD2014 Tmax values for plasma and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Median · h
Time to Maximum Observed Concentration (Tmax) for AZD2014 in Plasma and Saliva
h[14C]-AZD2014 (Period 1 [Day 1 - 8])
Tmax in plasma0.53 ± 37.73
Tmax in saliva1.00 (0.98 to 1.17)
PrimaryTime to Last Measurable Concentration (t[Last]) for AZD2014 in Plasma and Saliva

AZD2014 t(last) values in plasma and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · h
Time to Last Measurable Concentration (t[Last]) for AZD2014 in Plasma and Saliva
h[14C]-AZD2014 (Period 1 [Day 1 - 8])
t(last) in plasma17.04 ± 41.33
t(last) in saliva10.57 ± 21.76
PrimaryArea Under the Plasma Concentration-time Curve (AUC) for AZD2014

Mean AUC for AZD2014 following administration of \[14C\]-AZD2014 on Day 1 is presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve (AUC) for AZD2014
h*ng/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
Area Under the Plasma Concentration-time Curve (AUC) for AZD201417170 ± 29.80
PrimaryArea Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) for AZD2014 in Plasma and Saliva

Mean AUC(0-t) values in plasma and saliva for AZD2014 following administration of \[14C\]-AZD2014 on Day 1 are presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) for AZD2014 in Plasma and Saliva
h*ng/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
AUC(0-t) in plasma16510 ± 29.31
AUC(0-t) in saliva6025 ± 78.70
PrimaryApparent Total Body Clearance (CL/F) of AZD2014

The mean CL/F of AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · L/h
Apparent Total Body Clearance (CL/F) of AZD2014
L/h[14C]-AZD2014 (Period 1 [Day 1 - 8])
Apparent Total Body Clearance (CL/F) of AZD20147.282 ± 29.80
PrimaryMean Residence Time (MRT) of AZD2014

The MRT of AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · h
Mean Residence Time (MRT) of AZD2014
h[14C]-AZD2014 (Period 1 [Day 1 - 8])
Mean Residence Time (MRT) of AZD20145.200 ± 27.98
PrimaryApparent Volume of Distribution at Steady State (Vss/F) for AZD2014 in Plasma

The mean Vss/F of AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · L
Apparent Volume of Distribution at Steady State (Vss/F) for AZD2014 in Plasma
L[14C]-AZD2014 (Period 1 [Day 1 - 8])
Apparent Volume of Distribution at Steady State (Vss/F) for AZD2014 in Plasma37.86 ± 31.68
PrimaryTerminal Elimination Rate Constant (lambda_z) for AZD2014 in Plasma

The mean lambda_z of AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · 1/h
Terminal Elimination Rate Constant (lambda_z) for AZD2014 in Plasma
1/h[14C]-AZD2014 (Period 1 [Day 1 - 8])
Terminal Elimination Rate Constant (lambda_z) for AZD2014 in Plasma0.1941 ± 32.54
PrimaryHalf-life Associated With Terminal Slope (lambda_z) of a Semi-logarithmic Concentration-time Curve (t1/2[lambda_z]) for AZD2014 in Plasma

The mean t1/2(lambda_z) for AZD2014 in plasma following administration of \[14C\]-AZD2014 on Day 1 is presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h ost [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · h
Half-life Associated With Terminal Slope (lambda_z) of a Semi-logarithmic Concentration-time Curve (t1/2[lambda_z]) for AZD2014 in Plasma
h[14C]-AZD2014 (Period 1 [Day 1 - 8])
Half-life Associated With Terminal Slope (lambda_z) of a Semi-logarithmic Concentration-time Curve (t1/2[lambda_z]) for AZD2014 in Plasma3.571 ± 32.54
PrimaryCmax for Total [14C] Radioactivity in Whole Blood and Saliva

Mean \[14C\] radioactivity Cmax values in whole blood and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · ngEq/mL
Cmax for Total [14C] Radioactivity in Whole Blood and Saliva
ngEq/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
Cmax in whole blood3004 ± 36.91
Cmax in saliva6966 ± 76.90
PrimaryTmax for [14C] Radioactivity in Whole Blood and Saliva

\[14C\] radioactivity tmax in whole blood and saliva following administration of \[14C\]-AZD2014 on Day 1 is presented .

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Median · h
Tmax for [14C] Radioactivity in Whole Blood and Saliva
h[14C]-AZD2014 (Period 1 [Day 1 - 8])
tmax in whole blood0.53 ± 37.73
tmax in saliva1.00 (0.98 to 1.17)
PrimaryT(Last) for [14C] Radioactivity in Whole Blood and Saliva

Mean \[14C\] radioactivity t(last) values in whole blood and saliva following administration of \[14C\]-AZD2014 on Day 1 are presented.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose. Saliva was collected at 1, 2, 4, 6, 8, 10, 12 and 24 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · h
T(Last) for [14C] Radioactivity in Whole Blood and Saliva
h[14C]-AZD2014 (Period 1 [Day 1 - 8])
t(last) in whole blood18.26 ± 53.16
t(last) in saliva15.33 ± 39.24
PrimaryRatio of Whole Blood Total Radioactivity to Plasma Total Radioactivity

The mean ratios of whole blood total radioactivity to plasma total radioactivity are presented for the timepoints of sample collection up to 12 hours post-dose. Geometric mean ratios were not calculated after 12 hours.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h post [14C]-AZD2014 dose.
Reported as:
Geometric mean · ngEq/mL:ngEq/mL
Ratio of Whole Blood Total Radioactivity to Plasma Total Radioactivity
ngEq/mL:ngEq/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
0.5 h0.6861 ± 8.213
1 h0.6713 ± 9.982
1.5 h0.6825 ± 7.089
2 h0.6623 ± 5.377
3 h0.6750 ± 5.583
4 h0.6904 ± 8.647
6 h0.6797 ± 7.197
8 h0.6917 ± 11.16
12 h0.7211 ± 8.798
PrimaryRatio of AZD2014 Concentration to Total Radioactivity Concentration in Saliva

The mean ratios of saliva AZD2014 to saliva radioactivity concentrations are presented for the timepoints of saliva collection up to 10 hours post-dose. Geometric mean ratios were not calculated after 10 hours. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

Time frame:
Saliva was collected at 1, 2, 4, 6, 8 and 10 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · ng/mL:ngEq/mL
Ratio of AZD2014 Concentration to Total Radioactivity Concentration in Saliva
ng/mL:ngEq/mL[14C]-AZD2014 (Period 1 [Day 1 - 8])
1 h1.011 ± 5.350
2 h0.8217 ± 18.20
4 h0.7001 ± 6.167
6 h0.4993 ± 28.85
8 h0.4671 ± 45.52
10 h0.3648 ± 21.01
PrimaryFraction of AZD2014 Excreted in Urine as a Percentage of the Dose (fe%[R])

Mean fe%(R) values per urine collection period are presented as a percentage of the total \[14C\]-AZD2014 dose administered on Day 1.

Time frame:
Urine was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Mean · % of total [14C]-AZD2014 dose
Fraction of AZD2014 Excreted in Urine as a Percentage of the Dose (fe%[R])
% of total [14C]-AZD2014 dose[14C]-AZD2014 (Period 1 [Day 1 - 8])
0 - 6 h1.575 ± 1.165
6 - 12 h0.7471 ± 0.7198
12 - 24 h0.3472 ± 0.3251
24 - 48 h0.0460 ± 0.0697
48 - 72 h0 ± 0
72 - 96 h0 ± 0
96 - 120 h0 ± 0
120 - 144 hNA ± NA
144 - 168 h0 ± 0
PrimaryRenal Clearance (CL[R]) of AZD2014 From Plasma.

CL(R) of AZD2014 from plasma up to 168 h post-dose.

Time frame:
Blood samples collected: Day 1 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Geometric mean · L/h
Renal Clearance (CL[R]) of AZD2014 From Plasma.
L/h[14C]-AZD2014 (Period 1 [Day 1 - 8])
Renal Clearance (CL[R]) of AZD2014 From Plasma.0.1596 ± 78.34
PrimaryCumulative Percentage of Total [14C] Radioactivity Excreted in Urine as a Percentage of the Dose (fe Cum%[R])

fe cum%(R) by the end of each collection period is presented following administration of \[14C\]-AZD2014. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

Time frame:
Urine was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Mean · Cumulative % of total [14C]-AZD2014 dose
Cumulative Percentage of Total [14C] Radioactivity Excreted in Urine as a Percentage of the Dose (fe Cum%[R])
Cumulative % of total [14C]-AZD2014 dose[14C]-AZD2014 (Period 1 [Day 1 - 8])
0 - 6 h5.514 ± 3.917
0 - 12 h8.990 ± 4.711
0 - 24 h11.06 ± 5.130
0 - 48 h11.81 ± 5.294
0 - 72 h11.96 ± 5.378
0 - 96 h12.03 ± 5.416
0 - 120 h12.07 ± 5.441
0 - 144 h12.07 ± 5.441
0 - 168 h12.08 ± 5.453
PrimaryCumulative Percentage of Total [14C] Radioactivity Excreted in Stool as a Percentage of the Dose (fe Cum%[f])

fe cum%(f) by the end of each collection period is presented following administration of \[14C\]-AZD2014. Radioactivity excreta data for 1 patient was not included due to technical issues with radioactivity sample collection.

Time frame:
Stool was collected during the following periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h post [14C]-AZD2014 dose in the Single Dose Period.
Reported as:
Mean · Cumulative % of total [14C]-AZD2014 dose
Cumulative Percentage of Total [14C] Radioactivity Excreted in Stool as a Percentage of the Dose (fe Cum%[f])
Cumulative % of total [14C]-AZD2014 dose[14C]-AZD2014 (Period 1 [Day 1 - 8])
0 - 24 h18.23 ± 21.55
0 - 48 h52.85 ± 5.033
0 - 72 h77.04 ± 6.843
0 - 96 h78.59 ± 6.029
0 - 120 h79.25 ± 5.390
0 - 144 h79.70 ± 5.167
0 - 168 h79.94 ± 4.955
SecondaryNumber of AEs Experienced by Patients.

AEs (including serious AEs \[SAEs\]) were collected from the time of informed consent (Visit 1) and throughout the study, including the 30-day follow-up. The numbers of patients experiencing any AEs and SAEs, causally related AEs and SAEs, and SAEs which were fatal are presented.

Time frame:
From Day 1 of the Single Dose Period to 30 days after the last dose of AZD2014 administered in the Multiple Dose Period.
Reported as:
Number · Participants
Number of AEs Experienced by Patients.
Participants[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + Fulvestrant
Patients who experienced any AE31
Patients who experienced any causally related AE31
Patients who experienced any SAE11
Patients who experienced any causally related SAE00
Patients who experienced fatal SAE00
SecondaryBest Overall Response (BOR) Assessment

Anti-tumour activity through assessment of BOR. BOR was defined for each patient as follows according to the RECIST 1.1 criteria: Complete Response (CR): Disappearance of all target lesions since baseline. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions. Stable Disease (SD): Any cases that do not qualify for either PR or progressive disease (PD). PD: At least a 20% increase in the sum of the diameters of target lesions. BOR for each patient was determined as the best response recorded from the day study treatment started until progression or until the last evaluable RECIST tumour assessment in the absence of progression.

Time frame:
RECIST 1.1 assessments were performed pre-dose at screening and then once every 8 weeks relative to the start of treatment in the Multiple Dose Period.
Reported as:
Number · Participants
Best Overall Response (BOR) Assessment
Participants[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + Fulvestrant
Response: CR00
Response: PR00
Non-response: SD30
Non-response: Progression01
Non-response: Not evaluable00
SecondaryBest Percentage Change in Tumour Size From Baseline

Assessment of anti-tumour activity through measurement of tumour lesions. Tumour size was defined as the sum of the lengths of the longest diameters of the RECIST 1.1 target lesions.

Time frame:
RECIST 1.1 assessments were performed pre-dose at screening and then once every 8 weeks relative to the start of treatment in the Multiple Dose Period.
Reported as:
Median · Percentage change in tumour size
Best Percentage Change in Tumour Size From Baseline
Percentage change in tumour size[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + Fulvestrant
Best Percentage Change in Tumour Size From Baseline-8.75 (-13.0 to -4.5)3.1 (3.1 to 3.1)

Adverse events

Collected over TEAEs were collected from first dose of AZD2014 up to 30 days after the last dose. For patients who received AZD2014 monotherapy AEs were collected over approximately 11 months, and over approximately 2 months for those who received AZD2014 + fulvestrant.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
[14C]-AZD2014 Then AZD2014 Monotherapy—1/3 (33.3%)3/3 (100%)
[14C]-AZD2014 Then AZD2014 + Fulvestrant—1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
Event[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + Fulvestrant
Urinary Tract InfectionInfections and infestations0/31/1
MalaiseGeneral disorders1/30/1
Most frequent other events
Showing 10 of 31
Most frequent other events
Event[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + Fulvestrant
Candida infectionInfections and infestations0/31/1
Urinary tract infectionInfections and infestations0/31/1
AnaemiaBlood and lymphatic system disorders1/31/1
LeukopeniaBlood and lymphatic system disorders0/31/1
HyperphosphataemiaMetabolism and nutrition disorders0/31/1
MononeuropathyNervous system disorders0/31/1
PresyncopeNervous system disorders0/31/1
HypotensionVascular disorders0/31/1
Abdominal painGastrointestinal disorders0/31/1
Anal inflammationGastrointestinal disorders0/31/1

Baseline characteristics

All patients in the safety analysis set who received at least one dose of radiolabelled or non-radiolabelled AZD2014 were included in the baseline analysis.

Age, Categorical
Age, Categorical(Participants)[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + FulvestrantTotal
<=18 years000
Between 18 and 65 years213
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)[14C]-AZD2014 Then AZD2014 Monotherapy[14C]-AZD2014 Then AZD2014 + FulvestrantTotal
Female213
Male101
08

Study locations

1 site
  • Research Site
    Manchester, M20 4BX, United Kingdom
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02640755
Lead sponsor
AstraZeneca
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Dec 29, 2015
Start date
Jan 28, 2016
Primary completion
Dec 21, 2016
Completion
Jul 6, 2017
Results posted
Apr 22, 2019
Last update
Apr 22, 2019

Study contacts

Emma Dean, MD
principal investigator · The Christie NHS Foundation Trust

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

AstraZeneca

Start the discussion